| INTRODUC TI ON
Aging is a progressive deterioration of physiological functions accompanied by bone loss, leading to bone fragility, a disease that is known as osteoporosis (Singh, Brennan, et al., 2016) . With advancing age, the balance between bone formation and resorption is compromised, resulting in overall bone loss and structural damage. It has been confirmed that the impaired capacity of osteogenic differentiation of BMMSCs from the elderly people is a causative factor leading to age-related osteoporosis (Baker, Boyette, & Tuan, 2015) .
However, the underlying mechanisms that account for impaired osteogenic differentiation of aging BMMSCs remain unknown.
Calcium channels, which are in charge of calcium transportation into and out of cells and organelles, play an important role in aging (Surmeier, 2007; Warnier et al., 2018) . In terms of bone aging, numerous studies have indicated the relationship between disruption of calcium channels and age-related bone mass loss (Agacayak et al., 2014; Shimizu et al., 2012) . There are several kinds of calcium channels, among which voltage-gated Ca 2+ channels (VGCCs) are important components. They are formed by α1, α2δ, β, and γ subunits and are transmembrane surface proteins indispensable for many physiological events including membrane depolarizes, cellular motility, gene expression, and differentiation (Zamponi, Striessnig, Koschak, & Dolphin, 2015) . On the basis of the differences in α1 subunits, there are three families of VGCCs in mammals known as Ca v 1, Ca v 2, and Ca v 3 (Zamponi, 2016 (Silva et al., 2017; Zamponi, 2016) . Previous study confirmed that age-associated downregulation of Ca v 3.1 was involved in increased production of amyloid beta peptide 1-42 in N2a cells that led to neurodegenerative diseases (Rice, Berchtold, Cotman, & Green, 2014) . However, unlike other age-related diseases, the relationship between VGCCs and age-related bone loss remains a great dispute. Several studies showed that the activation of VGCCs played an important role in bone formation (Li, Duncan, Burr, Gattone, & Turner, 2003; Li, Duncan, Burr, & Turner, 2002; Noh, Park, Zheng, Ha, & Yim, 2011) , while others reported that inhibition of VGCCs could promote bone formation and suppress bone resorption (Marie, 2010; Ritchie, Maercklein, & Fitzpatrick, 1994) . Besides, whether and how VGCCs cause the decreased osteogenic differentiation of BMMSCs is poorly explored at the molecular level.
It has been widely acknowledged that canonical Wnt pathway plays a significant role in the regulation of BMMSCs osteogenic differentiation (Cook, Fellgett, Pownall, O'Shea, & Genever, 2014; Lin & Hankenson, 2011) . The canonical Wnt pathway causes an accumulation of β-catenin in the cytoplasm and its eventual translocation into the nucleus to act as a transcriptional coactivator. In Wnt signaling, GSK3β, a negative regulator of the canonical Wnt signaling, forms a multimeric complex with APC, AXIN1, and β-catenin and leads to β-catenin degradation by targeting it for ubiquitination.
Phosphorylation of GSK3β can interfere with the complex and block β-catenin degradation. Numerous studies have confirmed that inhibition of Wnt/β-catenin antagonists, such as sclerostin, DKK1, and WIF-1, can emerge as a promising therapeutic approach in the treatment of osteoporosis, and some are even in Phase III studies (Chen et al., 2014; Ke, Richards, Li, & Ominsky, 2012) . However, it remains unknown whether VGCCs could regulate osteogenic differentiation through canonical Wnt pathway.
Zmpste24 is a metalloproteinase that partakes in the maturation of lamin A. Zmpste24-deficient mice recapitulate many phenotypes observed in physiological aging, including reduced bone density and an increased risk of fracture (Ghosh & Zhou, 2014) .
The availability of Zmpste24-deficient mice could provide a new model to aid the study of mechanistic events underlying age-related osteoporosis. In this study, we provide insights into the importance of VGCCs in regulating age-related bone mass loss and the mechanism that underlie VGCCs mediated bone mass loss in Figure S1 . Firstly, we used micro-CT to measure relative density of bone mineral from 3-month-old wild-type and Zmpste24-deficient mice, and micro-CT images showed reduced mineralization of Zmpste24-deficient mice (Figure 1a ). Bone mineral density (BMD), bone volume/total volume (BV/TV), and trabecular number (Tb.N) were also significantly decreased in Zmpste24-deficient mice as measured by micro-CT densitometry (Figure 1b-d) . Besides, bone
formations were also significantly decreased as carried out by Table S1 ) and found changes of VGCCs associated genes, among which Ca v 1.2 was still downregulated (Figure S3a, b) .
Moreover, we also confirmed downregulated Ca v 1.2 expression of BMMSCs in natural aging model (Figure 1m ). To further confirm the change of Ca v 1.2 during aging process, we also investigated the protein level of Ca v 1.2. Western blot analysis showed that Ca v 1.2 protein was also downregulated in Zmpste24−/− and natural aging mice (Figure 1l ,n).
| Ca v 1.2 regulates osteogenic differentiation of aging BMMSCs
With the aim of investigating the potential role of Ca v 1.2 on impaired osteogenic differentiation of Zmpste24−/− BMMSCs, we modulated Ca v 1.2 expression levels in both wild-type and We also investigated the effect of Ca v 1.2 on adipogenic differentiation as BMMSCs exhibit an age-dependent reduction in osteogenic differentiation with an increased tendency toward adipocyte differentiation . Our results also confirmed the increased adipo- To investigate whether Ca v 1.2 regulated osteogenic differentiation through Wnt/β-catenin signaling, we used siRNA to knockdown and DMSO-treated wild-type mice. The treatment was initiated when male mice at 3 months of age and was given every 3 days.
After treating for two months, mice were sacrificed for Micro-CT analysis or processed to perform calcein labeling assay. As shown in Figure 5d -g, BMD, BV/TV, and Tb.N were significantly increased in Bay K8644-treated Zmpste24−/− mice compared to DMSO-treated Zmpste24−/− mice. In addition, Bay K8644 treatment also significantly enhanced bone formation as carried out by double-calcein F I G U R E 1 Ca v 1.2 is downregulated in aging BMMSCs with impaired osteogenic differentiation. (a) Bone masses of 3-month-old wildtype and Zmpste24-deficient mice were tested by micro-CT (n = 3), and the "interesting zone" was highlighted. (b-d) Bone mineral density (BMD), bone volume/total volume (BV/TV), and trabecular number (Tb.N) of 3-month-old wild-type and Zmpste24-deficient mice were analyzed with the micview software. (e) Bone formations of 3-month-old wild-type and Zmpste24−/− mice were examined by double-calcein labeling (n = 3). Scale bar, 25 um. (f) Mineral apposition rate (MAR) was analyzed by Image J under fluorescence microscope. (g) Expressions of osteogenic-related genes of ALP, Runx2, and OCN in wild-type and Zmpste24-deficient mice were detected by qRT-PCR after osteogenic induction for 5 days (n = 3). The results were normalized to GAPDH. (h) Expressions of osteogenic-related proteins of ALP, Runx2, and OCN in wild-type and Zmpste24-deficient mice were detected by Western blot after osteogenic induction for 7 days (n = 3). GAPDH was used as an internal control. (i) Mineralized nodules of BMMSCs from wild-type and Zmpste24-deficient mice were assayed by alizarin red staining after osteogenic induction for 14 days and quantified with a spectrophotometer after dissolving with cetylpyridinium chloride (n = 3). (j) Alizarin red staining was performed to detect mineralized nodules of BMMSCs from 3-month-old to 18-month-old normal mice after osteogenic induction for 14 days and quantified with a spectrophotometer after dissolving with cetylpyridinium chloride (n = 3). (k) Expressions of voltage-gated Ca 2+ channels (VGCCs) related genes in 3-month-old wild-type and Zmpste24-deficient mice were explored by qRT-PCR (n = 7). The results were normalized to GAPDH. (l) The protein level of Ca v 1.2 in 3-month-old wild-type and Zmpste24-deficient mice was explored by Western blot (n = 7). (m) Expression of Ca v 1.2 in 3-month-old young mice and 18-month-old natural aging mice was explored by qRT-PCR (n = 7). The results were normalized to GAPDH. (n) The protein level of Ca v 1.2 in 3-month-old young mice and 18-month-old natural aging mice was explored by Western blot (n = 7). Scale bar of alizarin red, 50 um. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, which was determined by unpaired two-tailed Student's t test labeling (Figure 5h,i) . However, we also found that BMD, BV/TV, and Tb.N were still lower compared with DMSO-treated wild-type group (Figure 5d-g ), which indicated that Bay K8644 could only partly ameliorate osteoporosis symptom. Consistent with such observations, double-calcein labeling also implied partial recovery of osteoporosis features after Bay K8644 treatment (Figure 5h,i) . 
| D ISCUSS I ON
In this study, we investigated the role of VGCCs played in regulating age-related bone mass loss and their potential mechanism. We found the bone mass of Zmpste24−/− mice was reduced and the osteo- cal aging, and our study also showed the defective bone phenotype of Zmpste24−/− mice and decreased osteogenic differentiation of Zmpste24−/− BMMSCs, which was consistent with previous report (Rivas, Li, Akter, Henderson, & Duque, 2009 ). It has been borne out by numerous studies that aberrant signal pathways are involved in age-related bone mass loss, including Notch (Roforth et al., 2014) and Wnt (Garcia-Velazquez & Arias, 2017) . These signaling pathways are intricate with a mixed network. Targeting the upstream regulatory mechanism may yield more effective results in treatment of age-related bone mass loss. VGCCs are the crucial influence factor of signal pathways and cell function. They encompass several channels with distinct functions (Striessnig, 2016) . For example, Ca v 1.1 can mediate the process of excitation-contraction coupling (Wu et al., 2016) , and Ca v 1.3 is associated with pace-making in dopaminergic neurons (Singh, Verma, et al., 2016) . Abnormity of these channels can lead to a variety of disorders (Zamponi et al., 2015) . Numerous studies have confirmed the engagement of VGCCs in age-related disease, including Parkinson disease (Ca v 1.3) (Zamponi et al., 2015) , ataxia (Ca v 2.1) (Dorgans et al., 2017 ), Alzheimer's disease (Ca v 3.1) (Rice et al., 2014) . Despite this, whether and how VGCCs exert influence on osteoporosis remains controversial. Several studies reported that the activation of VGCCs could promote bone formation (Li et al., 2003 (Li et al., , 2002 Noh et al., 2011) , while others found that inhibition of VGCCs could suppress osteogenesis (Marie, 2010; Ritchie et al., 1994) . In this study, we found decreased Ca v 1.2 expressions in several bone aging models, implying that Ca v 1.2 is an integral part of intricate mechanisms underlying age-related osteoporosis.
Ca v 1.2 is widely expressed in various tissues and regulates multiple cell functions. In term of cell differentiation, it participates in
the process of osteogenic (Wen et al., 2012) , odontogenic (Ju et al., 2015) , and neural differentiation (Obermair, Szabo, Bourinet, & Flucher, 2004 We further demonstrated the feasibility of Bay K8644 to treat age-related bone loss. However, despite the results that osteogenic differentiation deficiency and bone mass loss being improved upon receiving Bay K8644 stimulation, this method had limited effects as results from micro-CT and double-calcein labeling only showed partial recovery of osteoporosis features after Bay K8644 treatment. We ascribed it to the complex etiology of age-related bone mass loss as it is a disease involving multiple factors, of which defective osteogenic differentiation is just one element (Fossett, Khan, Pastides, & Adesida, 2012; Singh, Brennan, et al., 2016; Wang et al., 2014) . In terms of Zmpste24-deficient mice, age-related features mainly result from devastation of nuclear envelope and accumulation of progerin (Lee et al., 2016) . Therefore, looking for another upstream mechanism for age-related bone mass loss will be the focus of our future research on treating age-related bone mass loss.
In summary, we indicate that defective osteogenic differentiation Hong Kong, which have been described previously (Pendas et al., 2002) , and the wild-type mice were obtained from the breeding of Zmpste24+/-mice. Male littermates were used all through the study.
Genotype was identified via real-time polymerase chain reaction, and the primers are listed in Table S2 .
| Cell culture
Primary BMMSCs were isolated as previously described (Liao et al., 2016) . Briefly, BMMSCs from 3-month-old mice were obtained and cultured in α-MEM (Gibco BRL) supplemented with 20% fetal bovine serum (FBS; Thermo Electron), 0.292 mg/ml glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen). Cells were then plated in the 10 cm dish (Costar) at 37°C in 5% CO 2, and the medium was changed every 3 days. BMMSCs at passage 1 were used in the experiments. Bay K8644 (Abcam) was dissolved in DMSO (0.1% culture concentration).
| Osteogenic differentiation
Before osteogenic induction, 2 × 10 5 BMMSCs were seeded on 12-well culture dishes and cultured in the growth medium until the cells reached 80%-90% confluence as defined by area covered. BMMSCs were then cultured under osteogenic culture conditions containing 100 μg/ml ascorbic acid (Sigma), 5 mmol/l β-glycerophosphate (Sigma), and 10 nmol/l dexamethasone (Sigma). After osteogenic induction for 5 days, quantitative RT-PCR (qRT-PCR) was performed F I G U R E 3 Ca v 1.2 upregulates osteogenic differentiation of BMMSCs via Wnt/β-catenin pathway. (a) Expressions of GSK3β, p-GSK3β, β-catenin, and active-β-catenin in wild-type and Zmpste24−/− BMMSCs were detected by Western blot analysis (n = 7). (b) Wild-type BMMSCs were transfected with scramble siRNA or Ca v 1.2 siRNA, and the protein expression levels of GSK3β, p-GSK3β, β-catenin, and active-β-catenin were confirmed by Western blot analysis after 72 hr (n = 3). (c) Zmpste24−/− BMMSCs were transfected with control overexpression vector or Ca v 1.2 plasmid, and the protein expression levels of GSK3β, p-GSK3β, β-catenin, and active-β-catenin were confirmed by Western blot analysis after 72 hr (n = 3). (d) Wnt target genes of cyclin D1 and c-myc were explored in wild-type and Zmpste24−/− BMMSCs by qRT-PCR (n = 7). (e) Wild-type BMMSCs were transfected with scramble siRNA or Ca v 1.2 siRNA, and Wnt target genes of cyclin D1 and c-myc were explored by qRT-PCR (n = 3). (f) Zmpste24−/− BMMSCs were transfected with control overexpression vector or Ca v 1.2 plasmid, and Wnt target genes of cyclin D1 and c-myc were explored by qRT-PCR (n = 3). (g) 48 hr after transfection with control overexpression vector or Ca v 1.2 plasmid in progerin-overexpressed 293T cells, TOP/FOP, and Renilla luciferase plasmid were transfected, and TOP/FOP reporter assay was performed to detect the activity of β-catenin after 24 hr (n = 3). (h) Alizarin red staining of Zmpste24−/− and 5 mM LiCl-treated Zmpste24−/− BMMSCs was performed to detect mineralized nodules after osteogenic induction for 14 days (n = 3). (i) Expressions of osteogenic-related proteins of ALP, Runx2, and OCN in Zmpste24−/− BMMSCs from control group, Ca v 1.2-overexpressed and Ca v 1.2-overexpressed in the context of β-catenin siRNA were detected by Western blot after osteogenic induction for 7 days (n = 3), and each group contains equal volume of transfection agent. (j) Alizarin red staining of Zmpste24−/− BMMSCs from control group, Ca v 1.2-overexpressed and Ca v 1.2-overexpressed in the context of β-catenin siRNA were performed after osteogenic induction for 14 days (n = 3), and each group contains equal volume of transfection agent. The expression levels of the target proteins were normalized to GAPDH. Scale bar, 50 um. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, which was determined by paired two-tailed Student's t test , and 10 -8 M Bay K8644 for 3 days, intracellular calcium current of Zmpste24−/− BMMSCs was explored by laser confocal microscopy (n = 3). (c) After treated by DMSO or 10 -6 , 10
-7
, and 10 -8 M Bay K8644 for 3 days, intracellular calcium concentration of Zmpste24−/− BMMSCs was explored by flow cytometry (n = 3). (d) After treated by 10 -7 M Bay K8644 or DMSO for 3 days, the protein expression levels of GSK3β, p-GSK3β, β-catenin, and active-β-catenin in Zmpste24−/− BMMSCs were confirmed by Western blot analysis (n = 3). (e) After treated by 10 -7 M Bay K8644 or DMSO for 3 days, Wnt target genes of cyclin D1 and c-myc were explored by qRT-PCR (n = 3). (f) 48 hr after stimulated by DMSO or Bay K8644 in progerin-overexpressed 293T cells, TOP/FOP, and Renilla luciferase plasmid were transfected, and TOP/FOP reporter assay was performed to detect the activity of β-catenin after 24 hr (n = 3). (g) After osteogenic induction for 7 days, expressions of osteogenic-related proteins of ALP, Runx2, and OCN in Zmpste24−/− BMMSCs of DMSO-treated, Bay K8644-treated, and Bay K8644-treated in the context of Ca v 1.2 siRNA were explored (n = 3). (h) After osteogenic induction for 14 days, mineralized nodule formations in Zmpste24−/− BMMSCs of DMSO-treated, Bay K8644-treated and Bay K8644-treated in the context of Ca v 1.2 siRNA were explored (n = 3). The expression levels of the target genes and proteins were normalized to GAPDH. Scale bar, 50 um. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, which was determined by paired two-tailed Student's t test for the expressions of alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx2), and osteocalcin (OCN). Osteogenesis related proteins of ALP, Runx2, and OCN were assayed by Western blot after osteogenic induction for 7 days. Alizarin red staining was used to assess calcium deposit on day 14, and 10% cetylpyridinium chloride was added for quantitative analysis. The absorbance values were measured at 562 nm.
| Transfection assays
BMMSCs were seeded on twelve-well culture dishes and grown to 80%-90% confluence followed by serum starvation for 2h. Ca After intraperitoneal injection for 5 days, BMMSCs from DMSOtreated and Bay K8644-treated Zmpste24−/− mice were isolated, and intracellular calcium currents were tested by laser confocal microscopy (n = 7). (c) After intraperitoneal injection for 5 days, BMMSCs from DMSO-treated and Bay K8644-treated Zmpste24−/− mice were isolated, and intracellular calcium concentrations were tested by flow cytometry assay (n = 7). (d) After intraperitoneal injection for 2 months, bone masses of DMSO-treated wild-type, DMSO-treated Zmpste24−/−, and Bay K8644-treated Zmpste24−/− groups were tested by micro-CT (n = 6, 7 and 7). The "interesting zone" was highlighted. (e-g) BMD, BV/TV, and Tb.N were analyzed with the micview software (n = 6, 7 and 7). (h) After intraperitoneal injection for 2 months, bone formations of DMSO-treated wild-type, DMSO-treated Zmpste24−/−, and Bay K8644-treated Zmpste24−/− groups were examined by double-calcein labeling (n = 6, 7 and 7). Scale bar, 25 um. (i) Mineral apposition rate (MAR) was analyzed by Image J under fluorescence microscope. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, which was determined by unpaired two-tailed Student's t test F I G U R E 6 Bay K8644 rescues osteogenic differentiation ability of Zmpste24−/− BMMSCs in vivo. (a) After intraperitoneal injection for 2 months, the protein expression levels of GSK3β, p-GSK3β, β-catenin, and active-β-catenin of BMMSCs from DMSO-treated wild-type, DMSO-treated Zmpste24−/−, and Bay K8644-treated Zmpste24−/− mice were confirmed by Western blot analysis (n = 6, 7, and 7). (b) After intraperitoneal injection for 2 months, Wnt target genes of cyclin D1 and c-myc in BMMSCs from DMSO-treated wild-type, DMSO-treated Zmpste24−/−, and Bay K8644-treated Zmpste24−/− mice were explored by qRT-PCR (n = 6, 7, and 7). (c) After intraperitoneal injection for 2 months, expressions of osteogenic-related genes of ALP, Runx2, and OCN in BMMSCs from DMSO-treated wild-type, DMSO-treated Zmpste24−/−, and Bay K8644-treated Zmpste24−/− mice were detected by qRT-PCR after osteogenic induction for 5 days (n = 6, 7, and 7). (d) After intraperitoneal injection for 2 months, expressions of osteogenic-related proteins of ALP, Runx2, and OCN in BMMSCs from DMSO-treated wild-type, DMSO-treated Zmpste24−/−, and Bay K8644-treated Zmpste24−/− mice were detected by Western blot after osteogenic induction for 7 days (n = 6, 7, and 7). (e) After intraperitoneal injection for 2 months, alizarin red staining and quantification of BMMSCs from DMSO-treated wild-type, DMSO-treated Zmpste24−/−, and Bay K8644-treated Zmpste24−/− mice were performed to detect mineralized nodules after osteogenic induction for 14 days (n = 6, 7, and 7). (f) Schematic diagram shows that intraperitoneal injection of Bay K8644 improves defective osteogenic differentiation and ameliorates osteoporosis symptom through targeting Ca v 1.2 channel and canonical Wnt pathway of BMMSCs. The expression levels of the target genes and proteins were normalized to GAPDH. Scale bar, 50 um. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, which was determined by unpaired two-tailed Student's t test (addgene, Plasmid #26572) was transfected into BMMSCs at 500 ng.
For the control groups of siRNA or plasmid transfection experiments, scramble siRNA (RiboBio) or control overexpression vector pcDNA6/V5-His (Invitrogen) was included. Lipo2000 (Invitrogen) was used as a transfection reagent according to the manufacturer's instructions. After transfection, the culture medium was substituted by normal culture medium and cells were harvested at 48 hr for RNA and 72 hr for protein extraction. For detection of the osteogenic differentiation capacity, transfection medium was removed in the next day and replaced by osteogenic induction medium.
| Quantitative RT-PCR
Total cellular RNA was extracted from cells using the TRIzol reagent™ (Invitrogen) according to the manufacturer's instructions and cDNA was synthesized in a 20 μl reaction volume (Takara). The qRT-PCR reactions were performed in a total volume of 10 μl using the SYBR Premix Ex Taq™II kit (Takara) and then detected on the CFX96 RealTime System (Bio-Rad). Fold changes of mRNA were calculated by the 2 −ΔΔC t method after normalization to the expression of GAPDH.
The primer set sequences used for this study are listed in Table S3 .
| Western blot analysis
Cells were washed with PBS twice and lysed in RIPA lysis buffer 
| MTT assay
For the detection of cell proliferation, 1 × 10 4 Zmpste24−/− BMMSCs were seeded on ninety-six-well culture dishes. One day later (day 1), the culture medium was moved, and growth medium containing DMSO, 10 −6 M, 10 −7 M, and 10 −8 M Bay K8644 were added to the wells, respectively. MTT assay was performed on day 4. The process was as followed: First, 20 μl MTT (5 mg/ml in PBS) was added to the well; second, after culturing for 4 hr, the medium was carefully moved and 150 μl DMSO was added; and third, after vibrating for 10 min, the quantitative analysis was performed with 490 nm absorbance values. 
| Intracellular calcium concentration analysis

| Calcium imaging
For the calcium imaging, BMMSCs were incubated with 5 μM Fluo-3/AM dye for 30 min at 37°C, followed by washing with calibrated EGTA/Ca 2+ solutions for three times. Images were collected every 4 s at 2 Hz with excitation at 488 nm and emission at 530 nm by confocal laser microscopy (Zeiss, Oberkochen FV1000). 30 mM KCl was added to the culture medium at 60 s. Fluo-3 fluorescence intensity reflected intracellular Ca 2+ level, which was described previously (Merritt, McCarthy, Davies, & Moores, 1990) . The formula of Fluo-3 fluorescence intensity increase ratio is (F-F 0 )/F 0 . F means the fluorescence value detected and F 0 represents the minimum fluorescence value.
| Micro-CT analysis
To assess bone mass in mice, micro-CT (eXplore Locus SP, GE Healthcare) was used to scan femora. After sacrifice, bones were isolated and fixed in 4% paraformaldehyde overnight. The distal femoral metaphysis was scanned at a voltage of 80 kV with a current of 80 μA, and the voxel-size (mm) was (0.015898 × 0.015898 × 0.01 5898). The region of the trabecular bone for analyzing was defined from 0.1 to 1.5 mm away from the epiphyseal growth plate. The trabecular bone from each selected slice was segmented for three-dimension reconstruction. Parameters of BMD, BV/TV, and Tb.N were analyzed with the Micview software.
| Calcein labeling assay
Mice were intraperitoneal injected with 20 mg/kg calcein (Sigma)
at day 14 and day 2 before sacrifice. The femora were isolated and fixed in 80% ethanol at 4°C for 48 hr. After using graded ethanol to dehydrate, the femora were embedded in methyl methacrylate and longitudinal cut into 30 μm thick sections using a hard tissue slicing machine (SP1600, Leica). Bone dynamic histomorphometric analyses for mineral apposition rate (MAR) were performed according to the standardized nomenclature for bone histomorphometry under fluorescence microscopy (Leica DM 6000B, German).
| Statistical analyses
All experiments were repeated at least three times, and data are presented as mean ± SD. Comparisons between two groups were performed using paired or unpaired two-tailed Student's t test.
SPSS13.0 software was utilized, and a value of p < 0.05 was considered statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001). 
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